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Outcomes associated with bacteremia in the
setting of methicillin-resistant Staphylococcus
aureus pneumonia: a retrospective cohort study
Andrew F. Shorr1*, Marya D. Zilberberg2,3, Scott T. Micek4 and Marin H. Kollef5
Abstract
Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) remains an important pathogen in pneumonia.
Bacteremia may secondarily complicate MRSA pneumonia. The epidemiology and outcomes associated with
bacteremia in the setting of MRSA pneumonia are unknown. We sought to describe the prevalence of bacteremia
in MRSA pneumonia and its impact on hospital mortality and length of stay (LOS).
Methods: We conducted a single-center retrospective cohort study (2008–2013) including adult patients
hospitalized with pneumonia caused by MRSA. We defined pneumonia based on clinical criteria and all cases were
culture confirmed. MRSA bacteremia was identified based on positive blood cultures. Pneumonia was categorized
as either community-onset (CO, occurring at presentation or within 2 days of admission) or hospital-onset
(HO, occurring > 2 days after admission). We compared bacteremic and non-bacteremic groups with respect to
their demographic and clinical characteristics and outcomes. A logistic regression and a generalized linear model
(GLM) were constructed to examine the impact of bacteremia on hospital mortality and post-pneumonia onset
LOS, respectively.
Results: Among the 765 patients with MRSA pneumonia (33.1 % CO), 93 (12.2 %) had concurrent bacteremia
(37.6 % CO). Patients with bacteremia were similar to non-bacteremic subjects based on demographic and clinical
characteristics with the exception of frequency of a hospitalization within prior 180 days (48.4 % bacteremic and
37.7 % non-bacteremic, p = 0.047), prevalence of chronic liver disease (17.2 % vs. 9.5 %, p = 0.030), and the mean
APACHE II score at the onset of pneumonia (17.5 ± 6.0 vs. 16.1 ± 6.0, p = 0.045). Both unadjusted mortality
(33.7 % vs. 23.8 %, p = 0.067) and median post-pneumonia LOS (18.2 vs. 12.2 days, p < 0.001) were greater in the
bacteremic than the non-bacteremic group. In a logistic regression, bacteremia showed a trend toward an
association with increased mortality (odds ratio 1.56, 95 % confidence interval 0.93 to 2.61). Concomitant
bacteremia was independently associated with a 10.3-day increase in the post-pneumonia hospital LOS
(95 % confidence interval 6.7 to 13.9 days).
Conclusions: Concurrent bacteremia occurred with moderate frequency in the setting of hospitalization with MRSA
pneumonia. Although bacteremia did not appear to independently impact mortality, this was likely due to our
study’s limited sample size. However, bacteremia complicating MRSA pneumonia added between 1 and 2 weeks to
the hospital LOS.
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Introduction
Rates of infection due to methicillin-resistant Staphylococ-
cus aureus (MRSA) have been falling over the last 5 years
in both the United States and in Europe [1]. Despite this
trend, MRSA remains an important cause of pneumonia
and is associated with substantial morbidity and mortality.
Specifically, MRSA has been implicated as a pathogen in
healthcare-associated (HCAP), hospital-acquired (HAP),
and ventilator-associated (VAP) pneumonia [2]. In VAP in
the US, for example, MRSA represents the second most
common bacterial etiology for this infection [3]. More im-
portantly, crude in-hospital mortality rates in these vari-
ous MRSA pulmonary infections range from 10 to 30 %
[3, 4]. Furthermore, in the US the community-associated
strain of MRSA has been reported to be occasionally a
cause of community-acquired pneumonia (CAP) and to
lead to severe necrotizing infections [5]. In Europe,
although MRSA rates have declined rapidly, MRSA pneu-
monia continues to result in poor outcomes, and several
European experts have proposed MRSA pneumonia
guidelines to address this syndrome [6, 7].
Significant predictors of survival in MRSA pneumonia
include the timeliness of antibiotic therapy, severity of
illness at time of infection onset, and chronic underlying
conditions [8, 9]. Less certain is the importance of con-
current bacteremia in MRSA pneumonia. In skin and
skin structure infections caused by MRSA, secondary
bacteremia appears to occur in up to 10 % of patents,
but has no impact on mortality [8, 10]. With respect to
MRSA pneumonia, little is known about the prevalence
of bacteremia complicating this infection, as few reports
have analyzed this systematically. Those analyses that
have addressed bacteremia in MRSA pneumonia have,
generally, been small [11, 12]. Additionally, no information
exists regarding whether and how concurrent bacteremia
in MRSA pneumonia affects hospital length of stay (LOS),
a major determinant of healthcare costs.
In order to clarify these issues, we conducted a retro-
spective analysis of all patients with MRSA pneumonia
treated at a large, tertiary-care hospital. Specifically,
we sought to determine the prevalence of concurrent
bacteremia in MRSA pneumonia. Moreover, we aimed
to describe the impact of bacteremia on both hospital
mortality and hospital LOS.
Methods
Study overview
We retrospectively evaluated all subjects with MRSA
pneumonia admitted to a single institution (Barnes-Jewish
Hospital, St. Louis, MO, USA) between December 2008
and December 2013. The study only included adult pa-
tients (aged > 18 years) admitted through the emergency
department. We excluded those persons transferred
directly to the hospital from other institutions. We
also excluded patients with polymicrobial respiratory
infections. This project was approved by the Barnes-
Jewish Hospital institutional review board, and there
was no requirement for informed consent given our
retrospective design.
Pneumonia was identified based on traditional signs
and symptoms of chest infection. We further required
evidence of an infiltrate on chest imaging (e.g., either
chest radiograph or computed tomographic scan). All
radiology studies were reviewed by a single investigator
(M.H.K.). Cases were initially identified for possible
inclusion in the study cohort through a review of an
administrative database of all persons with a discharge
diagnosis of any type of pneumonia or of sepsis and
respiratory failure. These results were cross-referenced
with the hospital’s microbiology system to identify all
individuals with positive respiratory and blood cultures
showing MRSA (as described below). To be included,
patients must have had a respiratory culture which grew
MRSA along with the appropriate signs and evidence of
pneumonia. Subjects with abnormal chest imaging and
blood cultures revealing MRSA but in whom respiratory
cultures revealed no growth were excluded.
End points
In hospital, all-cause mortality served as the primary end
point. Hospital LOS following the infection onset repre-
sented a secondary end point.
Definitions and variables
Pneumonia was classified as CAP or HCAP if it was
diagnosed within 2 days of hospitalization. In contrast,
pneumonia was deemed HAP or VAP if it occurred 3 or
more days following admission to the hospital and was
not present on admission. VAP specifically required the
patient to be on mechanical ventilation for at least 24
hours prior to the infection’s onset. We defined pneumo-
nia as due to MRSA if sputum, lower airway, blood, or
pleural cultures were positive for MRSA. Patients without
a respiratory culture revealing MRSA were excluded. We
further ascertained if bacteremia complicated the patient’s
pneumonia. We defined bacteremia as present if at least
one blood culture was positive for MRSA. Only blood cul-
tures drawn within 48 hours of the onset of pneumonia
were reviewed in order to ensure that the pneumonia and
bacteremia were concurrent events. As part of institu-
tional protocol, all subjects with suspected pneumonia
undergo routine blood culture sampling (Bactec system,
Becton Dickson, Franklin Lakes, NJ, USA). We examined
a number of covariates, such as demographic variables
(age, sex, race), chronic disease burden (as individual co-
morbidities as well as their global burden as represented
by the Charlson score), acute illness severity (Acute Physi-
ology and Chronic Health Evaluation [APACHE] II score,
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need for mechanical ventilation and/or vasopressors), la-
boratory, physiological and treatment parameters [13, 14].
Statistical analyses
Continuous variables were reported as means with
standard deviations and as medians with 25th and 75th
percentiles. Differences between mean values were tested
via the Student’s t test, while those between medians
were examined using the Mann-Whitney U test. Cat-
egorical data were summarized as proportions, and the
chi-square test or Fisher’s exact test for small samples
was used to examine differences between groups. We
developed several multiple logistic regression models to
identify clinical risk factors for hospital mortality. In the
mortality models, all risk factors that were significant at
≤ 0.20 in the univariate analyses, as well as all biologic-
ally plausible factors, even if they did not reach this level
of significance, were included in the corresponding mul-
tivariable analyses. All variables entered into the models
were examined for collinearity, and interaction terms
were tested. The most parsimonious models were de-
rived using the backward manual elimination method,
and the best-fitting model was chosen based on the area
under the receiver operating characteristics curve
(AUROC or the c-statistic). The model’s calibration was
assessed with the Hosmer-Lemeshow goodness-of-fit test.
To examine the determinants of bacteremia-attributable
LOS, we constructed a generalized linear model (GLM)
with log-link to a Gaussian distribution. Model fit was
tested using Akaike information criterion (AIC) and
Bayesian information criterion (BIC) tests. All tests were
two-tailed. Because of sample size considerations, a p
value < 0.10 was deemed acceptable a priori to repre-
sent statistical significance for the mortality outcome.
All remaining tests of significance required alpha < 0.05.
All computations were performed in Stata/SE, version 9
(StataCorp, College Station, TX, USA).
Results
Among the 765 patients with MRSA pneumonia (33.1 %
CAP/HCAP), 93 (12.2 %) had concurrent bacteremia. At
baseline, patients with bacteremia were similar to non-
bacteremic subjects based on demographic and clinical
characteristics with the exception of frequency of a
hospitalization within the prior 180 days (48.4 % bac-
teremic and 37.7 % non-bacteremic, p = 0.047) and preva-
lence of chronic liver disease (17.2 % vs. 9.5 %, p = 0.030)
(Table 1). Reflecting this, the mean Charlson comorbidity
scores were 4.4 ± 3.3 and 4.2 ± 3.4 among bacteremic and
non-bacteremic patients, respectively, p = 0.340. At the
onset of pneumonia, while the mean APACHE II score
was higher among bacteremic subjects (17.5 ± 6.0 vs.
16.1 ± 6.0, p = 0.045), no significant differences were
observed between the groups in the rates of either
mechanical ventilation or vasopressor requirements
(Table 2). The median creatinine clearance (CrCl), how-
ever, was lower in the setting of bacteremia than in its ab-
sence (48, interquartile range [IQR] 26–67 vs. 56, IQR
33–79, p = 0.019). The most common initial antibiotic in
both the bacteremic and non-bacteremic subjects was
vancomycin, which was administered to nearly 80 % of
subjects empirically. The median time to first anti-MRSA
antibiotic administration appropriate for suspected pneu-
monia (i.e., vancomycin or linezolid) in both arms was less
than 2 hours (Table 2).
Unadjusted mortality (33.7 % vs. 23.8 %, p = 0.067)
and median post-pneumonia LOS (18.2 vs. 12.2 days,
p < 0.001) were greater in the bacteremic than the
non-bacteremic group (Table 3, Fig. 1). There were no
differences in the discharge destination, with the propor-
tion discharged to home as opposed to a nursing home
similar between the groups.
In a logistic regression, bacteremia showed a trend to-
ward an association with increased mortality at the alpha
level of 0.050, (odds ratio 1.56, 95 % confidence interval
[CI] 0.93 to 2.61), and was significantly associated with it
at the level of p < 0.100 (90 % CI 1.01 to 2.40) (Table 4).
Other variables associated with an increased risk of death
included measures of disease severity such as the need for
mechanical ventilation and the APACHE II score. This
model demonstrated a good fit with a Hosmer-Lemeshow
p = 0.910 and an AUROC of 0.75. Concomitant bac-
teremia was independently associated with a 10.3-day in-
crease in the attributable post-pneumonia onset hospital
LOS (95 % CI 6.7 to 13.9 days, p < 0.001) (Table 5). This
model for attributable LOS also had a good fit with an
AIC of 8.35. Pneumonia type, which was entered into the
model, was not retained in the final model as a significant
predictor.
Discussion
This large retrospective analysis indicates that bacteremia
complicates nearly one in seven cases of MRSA pneumo-
nia. Although we failed to note an independent impact of
secondary bacteremia on hospital mortality, this likely re-
flects our limited sample size rather that a true absence of
an effect. In addition, MRSA bacteremia as a component
of MRSA pneumonia adds to the attributable LOS and
thus increases hospital costs.
Prior efforts to address the importance of concurrent
bacteremia in MRSA pneumonia have been limited. In
an analysis of approximately 600 patients with either
nosocomial pneumonia or VAP, Magret and coworkers
noted that bacteremia occurred in 15 % of subjects,
similar to the rate we report. [15] Magret et al., though,
included all subjects with either HAP or VAP, irrespective
of pathogen [15]. In fact, MRSA accounted for less than
16 % of their study cohort. Nonetheless, they observed
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that concurrent MRSA bacteremia independently corre-
lated with a higher risk for death. Exploring the issue of
the interaction between pneumonia and bloodstream in-
fection from a different perspective, Turnidge et al. ana-
lyzed predictors of mortality in a cohort of nearly 2000
patients with S. aureus bacteremia, including both those
with methicillin-susceptible S. aureus and MRSA infection
[16]. Persons with concurrent pneumonia and bacteremia
only comprised a small aspect of their population (7.8 %)
[16]. Pneumonia as the primary infection site, though, ap-
peared to confer a higher risk for death.
In one of the larger efforts to describe variables associ-
ated with mortality in MRSA pneumonia, Haque and
colleagues analyzed 251 cases of MRSA pneumonia [12].
As others have shown, severity of illness was the main
driver of outcomes. However, they failed to even exam-
ine concurrent bacteremia as a potential factor affecting
eventual survival [12]. Finally, Schreiber et al. specifically
Table 1 Baseline characteristics
Bacteremia + Bacteremia − P value
N % N %
93 12.16 % 672 87.84 %
Age, yrs
Mean [SD] 58.4 [14.1] 58.8 [17.8]
Median (IQR) 58.5 (53.4, 67.6) 60.8 (48.1, 72.3) 0.622
Race
Caucasian 51 54.84 % 424 63.10 % 0.392
African-American 39 41.94 % 213 31.70 %
Asian 0 0.00 % 5 0.74 %
Other 0 0.00 % 6 0.89 %
Unknown 3 3.23 % 24 3.57 %
Gender, female 35 37.63 % 290 43.15 % 0.580
BMI
Mean [SD] 28.6 [9.1] 29.0 [10.1]
Median (IQR) 27.5 (21.9, 33.5) 26.9 (22.2, 33.3) 0.941
Hospitalization in previous 180 days 45 48.39 % 253 37.65 % 0.047
Comorbidities
MI 12 12.90 % 74 11.01 % 0.599
CHF 21 22.58 % 140 20.83 % 0.685
PVD 13 13.98 % 82 12.20 % 0.616
CVD 11 11.83 % 74 11.01 % 0.860
Dementia 3 3.23 % 11 1.64 % 0.237
COPD 30 32.26 % 210 31.25 % 0.905
Connective tissue disease 2 2.15 % 22 3.27 % 0.757
PUD 6 6.45 % 24 3.57 % 0.246
CLD 16 17.20 % 64 9.52 % 0.030
DM 25 26.88 % 158 23.51 % 0.517
CKD 20 21.51 % 99 14.73 % 0.095
CA 19 20.43 % 142 21.13 % 1.000
HIV 1 1.08 % 4 0.60 % 0.478
Charlson score
Mean [SD] 4.4 [3.3] 4.2 [3.4]
Median (IQR) 4 (2, 6) 3 (1, 6) 0.340
SD standard deviation, IQR interquartile range, BMI body mass index, MI myocardial infarction, CHF congestive heart failure, PVD peripheral vascular disease, CVD
cerebrovascular disease, COPD chronic obstructive pulmonary disease, PUD peptic ulcer disease, CLD chronic liver disease, DM diabetes mellitus, CKD chronic
kidney disease, CA cancer, HIV human immunodeficiency virus
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Table 2 Pneumonia and treatment characteristics
Bacteremia + Bacteremia − P value
N % N %
93 12.16 % 672 87.84 %
Pneumonia characteristics
Pre-pneumonia LOS, days
Mean [SD] 11.3 [15.0] 8.6 [13.7]
Median (IQR) 4.7 (1.1, 15.8) 4.6 (0.9, 11) 0.333
ICU prior to pneumonia 15 16.13 % 94 13.99 % 0.634
Pneumonia type
CAP or HCAP 35 37.63 % 218 32.44 % 0.318
HAP or VAP 58 62.37 % 454 67.56 %
ICU at onset of pneumonia 66 70.97 % 485 72.17 % 0.806
ICU transfer after pneumonia onset 5 5.38 % 19 2.83 % 0.198
No ICU during pneumonia admission 7 7.53 % 73 10.86 % 0.372
Specimen type
Bronchial brushing 0 0.00 % 1 0.15 % 0.565
Bronchial washing 8 8.60 % 33 4.91 %
Bronchoalveolar lavage 7 7.53 % 55 8.18 %
Sputum 7 7.53 % 73 10.86 %
Induced sputum 4 4.30 % 23 3.42 %
Tracheal aspirate 67 72.04 % 487 72.47 %
Illness severity
Mechanical ventilation 71 76.34 % 499 74.26 % 0.705
Vasopressors 40 43.01 % 228 33.93 % 0.104
APACHE II (at pneumonia onset)
Mean [SD] 17.5 [6.0] 16.1 [6.0]
Median (IQR) 16 (13, 22) 16 (12, 20) 0.045
Day of pneumonia onset peak WBC
Mean [SD] 15.4 [7.2] 15.3 [12.5]
Median (IQR) 14.2 (10.5, 21.2) 13.5 (10, 17.9) 0.232
Day of pneumonia onset peak temperature, C
Mean [SD] 38.1 [1.1] 38.1 [1.0]
Median (IQR) 38.2 (37.5, 38.9) 38.2 (37.3, 38.8) 0.834
CrCl (at pneumonia onset)
Mean [SD] 50.78 ± 31.42 58.84 ± 32.44 0.019
Median (IQR) 48 (26, 67) 56 (33, 79)
CrCl > 50 (at pneumonia onset) 43 46.24 % 379 56.40 % 0.065
Treatment characteristics
Time to first drug, hrs
Mean [SD] 8.7 [21.7] 17.6 [41.7]
Median (IQR) 0.1 (0.1, 4.0) 0.1 (0.1, 18.6) 0.007
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explored the potential significance of secondary bac-
teremia in MRSA pneumonia. They concluded that
bacteremia was seen in 20 % of cases of MRSA pneumo-
nia and that bacteremia independently increased the risk
for death sixfold. However, this analysis included only 59
subjects and enrolled both those with MRSA and MRSA
pneumonia [11]. Reflecting concerns about the serious-
ness of MRSA as a cause of pneumonia, some have pro-
posed specific MRSA pneumonia treatment paradigms
based on the presence or absence of bacteremia, and our
results demonstrate the importance of this confounding
issue (6.7).
Our study expands on these earlier reports. We confirm
a general association between concomitant bacteremia
and worse outcomes in MRSA pneumonia. Unlike prior
analyses, we evaluated a large cohort of MRSA pneumo-
nia. Furthermore, our cohort was fairly heterogeneous in
that it included all cases of MRSA pneumonia, irrespective
of pneumonia subtype (e.g., HCAP vs. VAP). This fact
helps to establish the generalizability of our findings. The
relatively large sample size additionally allows us to better
control for a variety of confounders that others could not
address as fully. We also establish that concurrent
bacteremia adds substantially to hospital LOS. This obser-
vation is novel as others have not examined this issue pre-
viously. The deleterious impact on LOS is independent of
multiple potential confounders. Given that bacteremia re-
mains associated with a greater LOS, our findings suggest
that future studies should focus on this cohort of patients
in order to determine if some different treatment para-
digm might mitigate the negative impact of concurrent
bacteremia on LOS. Finally, all patients in this report
received timely therapy, reducing the risk that an initial
delay in antibiotic treatment confounds our conclusions.
Why might the simultaneous presence of MRSA pneu-
monia and bacteremia lead to worse patient outcomes?
Host factors such as underlying comorbidities could ex-
plain some of this connection. For example, patients
with bacteremia were more likely to suffer from liver
disease than those whose pneumonia was not compli-
cated by bacteremia. However, it seems unlikely that
chronic host issues alone account for the excess burden
Table 2 Pneumonia and treatment characteristics (Continued)
Drug
Ceftaroline 6 6.45 % 12 1.79 % 0.015
Daptomycin 13 13.98 % 13 1.93 % <0.001
Linezolid 47 50.54 % 219 32.59 % 0.001
Vancomycin 83 89.25 % 559 83.18 % 0.174
Time to drug, hrs
Ceftaroline
Mean [SD] 582.7 [562.5] 382.1 [653.6]
Median (IQR) 448.9 (69.6, 1,180.5) 150.2 (16.6, 440.5) 0.426
Daptomycin
Mean [SD] 172.7 [252.0] 648.7 [874.6]
Median (IQR) 54.3 (0.1, 187.7) 430.4 (236.7, 580) 0.017
Linezolid
Mean [SD] 117.3 [171.9] 138.9 [225.8]
Median (IQR) 46.5 (12.2, 157.7) 67.3 (23.0, 170.8) 0.280
Vancomycin
Mean [SD] 0.9 [0.3] 0.8 [0.4]
Median (IQR) 1 (1, 1) 1 (1, 1) 0.110
Number of anti-MRSA drugs used
0 5 5.38 % 85 12.65 % <0.001
1 36 38.71 % 386 57.44 %
2 43 46.24 % 187 27.83 %
3 9 9.68 % 13 1.93 %
4 0 0.00 % 1 15.00 %
LOS length of stay, SD standard deviation, IQR interquartile range, ICU intensive care unit, CAP community-acquired pneumonia, HCAP healthcare-associated
pneumonia, HAP hospital-acquired pneumonia, VAP ventilator-associated pneumonia, APACHE Acute Physiology and Chronic Health Evaluation, WBC white blood
cells, CrCl creatinine clearance, MRSA methicillin-resistant Staphylococcus aureus
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of bacteremia. The absence of any baseline host factors
in either the mortality or LOS models indicates that
these types of variables likely contribute little to overall
outcomes. Alternatively, bacteremia might lead to more
severe illness. The presence of bacteria in the blood
could theoretically potentiate a cytokine cascade result-
ing in a more robust systemic inflammatory response.
Conversely, bacteremia might simply reflect poor initial
source control and a greater organism burden. In either
event, the effect of secondary bacteremia on outcomes
in MRSA pneumonia likely arises due a complex inter-
action between the host and the pathogen. However, this
relationship is likely more complex than our current
tools allow us to elucidate. Haque et al., for instance, an-
alyzed a number of variables related to the bacteria to
include its SECmec type, pulsed-field gel electropheresis
Fig. 1 Plot of post-pneumonia onset LOS stratified by bacteremia. LOS length of stay
Table 3 Unadjusted outcomes
Bacteremia + Bacteremia − P value
N % N %
93 12.16 % 672 87.84 %
Post-pneumonia onset LOS, days
Mean [SD] 25.8 [26.6] 15.8 [16.0]
Median (IQR) 18.2 (8.1, 31.3) 12.2 (6.1, 19.9) <0.001
Total LOS, days
Mean [SD] 37.1 [33.5] 24.4 [22.8]
Median (IQR) 29.5 (12.8, 46.1) 18.3 (9.9, 31.2) <0.001
Discharge destination
Home 6 6.45 % 84 12.50 % 0.067
Rehab 13 13.98 % 97 14.43 %
LTAC 13 13.98 % 62 9.23 %
SNF 19 20.43 % 134 19.94 %
Home with home health services 7 7.53 % 106 15.77 %
Othera 4 4.30 % 31 4.61 %
Died during hospitalization 31 33.70 % 158 23.80 %
Died during hospitalization or sent home with hospice care 32 34.41 % 165 24.55 % 0.042
LOS length of stay, SD standard deviation, IQR interquartile range, LTAC long-term acute care, SNF skilled nursing facility
aCategory of discharge “other” includes: against medical advice (n = 4), home with hospice care (n = 8), licensed nursing facility (n = 1), psychiatric unit (n = 1),
federal hospital (n = 7), other short-term hospital (n = 5), missing (n = 9)
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type, Panton-Valentine leukocidin toxin gene presence
and their connection with mortality in MRSA pneu-
monia [12]. None of these aspects of the culprit MRSA
appeared to alter mortality in MRSA pneumonia. Further-
more, the longer LOS may reflect, in part, the choices
used to treat patients with concurrent bacteremia. With
bacteremia nearly all patients received intravenous gly-
copeptides. As such, this may have either prolonged
hospitalization as outpatient antibiotic therapy was ar-
ranged or because outpatient infusion was not an option
in select cases. Our findings, hence, may reflect an issue
with the choices we have for this serious disease as op-
posed to some aspect of the bacteremia itself. However,
even if this possibility explains some of the difference in
LOS between those with and those lacking bacteremia,
our data continue to represent a “real world” assessment
of the burden of bacteremia in MRSA pneumonia.
Our study has a number of significant limitations.
First, its retrospective design opens it to various forms
of bias. Specifically, selection bias certainly may have af-
fected our findings. Similarly, ascertainment bias in the
identification of bacteremias, due to both the limitations
of blood cultures and the frequency with which they are
drawn, likely plays a role in our findings. However, we
focused on end points such as mortality and LOS, which
are not prone to ascertainment or recall bias. We also
lacked consistent data on several variables such as the
post-infection onset duration of mechanical ventilation.
Second, the data derive from a single center and this ne-
cessarily limits the generalizability of our findings. In
that same vein, the vast majority of our subjects received
vancomycin for initial therapy. As such, our results may
not be reflective of what one might see if other agents
had been employed empirically. Third, despite being a
rather large cohort, we nevertheless may have lacked
power to adjust for certain confounders that could affect
either of our end points. Furthermore, pneumonia itself
can represent a difficult diagnosis. To address this con-
cern we utilized precise criteria for the diagnosis of pul-
monary infection and had one reviewer examine all
chest imaging studies. Fourth, nearly every patient in the
study was given vancomycin initially. It remains unclear
if vancomycin represents the optimal choice for MRSA
pneumonia and therefore our findings might have been
different if subjects were treated with other alternative
options. With respect to vancomycin, also, we lack data
about trough levels. Hence our results may have been
skewed by inappropriate dosing even if patients received
timely antibiotics. Fifth, given that in some cases patients
Table 5 Attributable hospital length of stay in days
Parameter Point estimate 95 % CI P value
Bacteremia 10.3 6.7 to 13.9 <0.001
Mechanical ventilation 6.8 3.8 to 9.8 <0.001
Vasopressors 5.6 3.0 to 8.1 <0.001
Time from admission to
pneumonia onset (per 1 day)
0.11 0.06 to 0.15 <0.001
Time to anti-MRSA treatment
(per 1 hour)
0.03 0.01 to 0.05 0.002
In-hospital mortality −5.8 −8.4 to −3.2 <0.001
AIC = 8.35
BIC = 156153.9
CI confidence interval, MRSA methicillin-resistant Staphylococcus aureus
Table 4 Predictors of mortality
Parameter OR 95 % CI 90 % CI P value
Mechanical ventilation 3.18 1.79 to 5.64 1.96 to 5.14 0.001
Bacteremia 1.56 0.93 to 2.61 1.01 to 2.40 0.091
Vasopressors 1.46 1.01 to 2.12 1.07 to 2.00 0.047
APACHE II (per 1 point) 1.09 1.06 to 1.13 1.06 to 1.12 <0.001
Day of pneumonia onset peak T, C (per 0.1 degree) 0.76 0.63 to 0.92 0.65 to 0.89 0.004
ICU prior to pneumonia 0.29 0.14 to 0.61 0.16 to 0.54 0.001
AUROC = 0.750
Hosmer-Lemeshow goodness-of-fit p = 0.910
-Factors included but not retained at the p value of < 0.1:
Age, BMI, CAP/HCAP, day of pneumonia onset peak WBC, peak WBC over 7 days after pneumonia onset, CrCl > 50
-Factors excluded for perfect prediction:
ICU transfer after pneumonia onset, no ICU during pneumonia admission
-Factors excluded for collinearity:
Charlson, pre-pneumonia LOS, ICU at onset of pneumonia
OR odds ratio, CI confidence interval, APACHE Acute Physiology and Chronic Health Evaluation, ICU intensive care unit, AUROC area under the receiver operating
curve, BMI body mass index, CAP community-acquired pneumonia, HCAP healthcare-associated pneumonia, WBC white blood cells, CrCl creatinine clearance, LOS
length of stay
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could have had multiple primary infections occurring
concurrently (e.g., a catheter-associated bloodstream in-
fection and a pneumonia) that were misconstrued as one
diagnosis, we may have overestimated the frequency of
bacteremia complicating MRSA pneumonia. Finally, we
could not classify MRSA isolates as to their genotypes
(e.g., USA 300 vs. USA 400 strains). Historically in our
hospital, USA 300 has been a rare cause of any type of
pneumonia. Hence the results we report may not be ap-
plicable to settings where the USA 300 strain is far more
prevalent.
Conclusions
In conclusion, concurrent bacteremia in MRSA pneu-
monia appeared to occur with moderate frequency. Al-
though bacteremia’s impact on mortality did not reach
statistical significance at alpha < 0.05, this was likely due
to our study’s limited sample size. However, bacteremia
complicating MRSA pneumonia added between 1 and 2
weeks to the hospital LOS.
Key messages
 Concurrent bacteremia occurred in 12 % of
intensive care unit (ICU) patients with MRSA
pneumonia
 There was a trend toward increased hospital
mortality among patients with concurrent
bacteremia compared to those without
 Concurrent bacteremia in the setting of MRSA
pneumonia was associated with an increase in the
hospital LOS of 1–2 weeks
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